Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 10/10

vs
industry
vs
history
Cash to Debt No Debt
NAS:VASC's Cash to Debt is ranked higher than
99% of the 326 Companies
in the Global Medical Devices industry.

( Industry Median: 2.32 vs. NAS:VASC: No Debt )
Ranked among companies with meaningful Cash to Debt only.
NAS:VASC' s Cash to Debt Range Over the Past 10 Years
Min: 1.11  Med: No Debt Max: No Debt
Current: No Debt
Equity to Asset 0.91
NAS:VASC's Equity to Asset is ranked higher than
96% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 0.63 vs. NAS:VASC: 0.91 )
Ranked among companies with meaningful Equity to Asset only.
NAS:VASC' s Equity to Asset Range Over the Past 10 Years
Min: 0.34  Med: 0.87 Max: 0.96
Current: 0.91
0.34
0.96
Interest Coverage No Debt
NAS:VASC's Interest Coverage is ranked higher than
99% of the 221 Companies
in the Global Medical Devices industry.

( Industry Median: 73.78 vs. NAS:VASC: No Debt )
Ranked among companies with meaningful Interest Coverage only.
NAS:VASC' s Interest Coverage Range Over the Past 10 Years
Min: 48.63  Med: 1211.19 Max: No Debt
Current: No Debt
F-Score: 6
Z-Score: 43.82
M-Score: -2.21
WACC vs ROIC
9.44%
13.56%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 8.33
NAS:VASC's Operating margin (%) is ranked higher than
66% of the 308 Companies
in the Global Medical Devices industry.

( Industry Median: 2.42 vs. NAS:VASC: 8.33 )
Ranked among companies with meaningful Operating margin (%) only.
NAS:VASC' s Operating margin (%) Range Over the Past 10 Years
Min: -8.18  Med: 13.25 Max: 17.33
Current: 8.33
-8.18
17.33
Net-margin (%) 7.57
NAS:VASC's Net-margin (%) is ranked higher than
70% of the 308 Companies
in the Global Medical Devices industry.

( Industry Median: 1.87 vs. NAS:VASC: 7.57 )
Ranked among companies with meaningful Net-margin (%) only.
NAS:VASC' s Net-margin (%) Range Over the Past 10 Years
Min: -8.15  Med: 10.08 Max: 27.25
Current: 7.57
-8.15
27.25
ROE (%) 9.26
NAS:VASC's ROE (%) is ranked higher than
68% of the 303 Companies
in the Global Medical Devices industry.

( Industry Median: 1.47 vs. NAS:VASC: 9.26 )
Ranked among companies with meaningful ROE (%) only.
NAS:VASC' s ROE (%) Range Over the Past 10 Years
Min: -31.56  Med: 13.33 Max: 72.44
Current: 9.26
-31.56
72.44
ROA (%) 8.28
NAS:VASC's ROA (%) is ranked higher than
79% of the 330 Companies
in the Global Medical Devices industry.

( Industry Median: 0.20 vs. NAS:VASC: 8.28 )
Ranked among companies with meaningful ROA (%) only.
NAS:VASC' s ROA (%) Range Over the Past 10 Years
Min: -16.48  Med: 11.29 Max: 42.87
Current: 8.28
-16.48
42.87
ROC (Joel Greenblatt) (%) 18.98
NAS:VASC's ROC (Joel Greenblatt) (%) is ranked higher than
69% of the 325 Companies
in the Global Medical Devices industry.

( Industry Median: 3.44 vs. NAS:VASC: 18.98 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NAS:VASC' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -28.47  Med: 39.66 Max: 56.54
Current: 18.98
-28.47
56.54
Revenue Growth (3Y)(%) 10.90
NAS:VASC's Revenue Growth (3Y)(%) is ranked higher than
74% of the 233 Companies
in the Global Medical Devices industry.

( Industry Median: 3.90 vs. NAS:VASC: 10.90 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NAS:VASC' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 8.8  Med: 12.9 Max: 89.2
Current: 10.9
8.8
89.2
EBITDA Growth (3Y)(%) -2.80
NAS:VASC's EBITDA Growth (3Y)(%) is ranked lower than
61% of the 195 Companies
in the Global Medical Devices industry.

( Industry Median: 4.00 vs. NAS:VASC: -2.80 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NAS:VASC' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -63.8  Med: -5.15 Max: 265.1
Current: -2.8
-63.8
265.1
EPS Growth (3Y)(%) -1.10
NAS:VASC's EPS Growth (3Y)(%) is ranked lower than
54% of the 196 Companies
in the Global Medical Devices industry.

( Industry Median: 2.70 vs. NAS:VASC: -1.10 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NAS:VASC' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -67.4  Med: -14.75 Max: 22.1
Current: -1.1
-67.4
22.1
» NAS:VASC's 10-Y Financials

Financials (Next Earnings Date: Est. 2017-04-25)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

VASC Guru Trades in Q4 2015

Jim Simons 480,800 sh (-0.74%)
Mario Gabelli 229,200 sh (-0.78%)
Mairs and Power 69,853 sh (-8.75%)
Chuck Royce 114,485 sh (-26.35%)
» More
Q1 2016

VASC Guru Trades in Q1 2016

Mairs and Power 75,553 sh (+8.16%)
Jim Simons 496,700 sh (+3.31%)
Chuck Royce Sold Out
Mario Gabelli 227,200 sh (-0.87%)
» More
Q2 2016

VASC Guru Trades in Q2 2016

Mairs and Power 75,653 sh (+0.13%)
Mario Gabelli 211,800 sh (-6.78%)
Jim Simons 442,700 sh (-10.87%)
» More
Q3 2016

VASC Guru Trades in Q3 2016

Mairs and Power 75,453 sh (-0.26%)
Mario Gabelli 208,300 sh (-1.65%)
Jim Simons 327,800 sh (-25.95%)
» More
» Details

Insider Trades

Latest Guru Trades with VASC

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices    NAICS: 334510    SIC: 3845
Compare:NAS:SPNC, NYSE:ITGR, NAS:CSII, NAS:CYNO, NAS:MDXG, NAS:KTWO, NAS:OFIX, NYSE:CRY, NAS:CNMD, OTCPK:IOBCF, NAS:INGN, NAS:GNMK, NAS:BABY, OTCPK:MZRTF, NAS:ARAY, NAS:EXAC, NYSE:IVC, OTCPK:NMRD, OTCPK:IPDQF, NAS:XENT » details
Traded in other countries:VA4.Germany,
Vascular Solutions Inc is a medical device company. It is engaged in providing solutions to interventional cardiologists and interventional radiologists.

Vascular Solutions Inc was incorporated in the state of Minnesota in December 1996. It is a medical device company, creates new minimally invasive medical devices, and delivers these products and related services to physicians through its direct domestic sales force and its international distribution network. The Company's products and services are divided into three categories: Catheter products; Hemostat products and Vein products and services. Catheter products consist principally of catheters used in minimally invasive medical procedures for the diagnosis or treatment of vascular conditions, such as the GuideLiner catheter used to access discrete regions of the coronary anatomy and the Pronto extraction catheters used in treating acute myocardial infarction. Hemostat products consist principally of blood clotting products, such as the D-Stat Dry hemostat, a topical thrombin-based pad with a bandage used to control surface bleeding, and the D-Stat Flowable, a thick yet flowable thrombin-based mixture for preventing bleeding in subcutaneous pockets. Vein products and services consist principally of the Vari-Lase endovenous laser, a laser console and procedure kit used for the treatment of varicose veins, and a reprocessing service for the ClosureFAST radiofrequency vein ablation catheter. The Company manufactures its products in its facilities located in the suburbs of Minneapolis, Minnesota and in the country of Ireland. The catheter manufacturing and packaging processes occur under a controlled clean room environment. It purchases components from various suppliers and rely on single sources for several parts of its products. It purchases its requirements for thrombin for use in manufacturing products sold in the U.S. under the Thrombin-JMI Supply Agreement with King. Its main competitors include: Medtronic, Boston Scientific, Covidien, Merit Medical, Marine Polymer Technologies, Cook Medical, Spectranetics, AngioDynamics and Terumo. The Company's products and services are regulated in the United States as medical devices by the FDA under the Federal Food, Drug and Cosmetic Act.

Ratios

vs
industry
vs
history
P/E(ttm) 79.65
VASC's P/E(ttm) is ranked lower than
85% of the 172 Companies
in the Global Medical Devices industry.

( Industry Median: 25.16 vs. VASC: 79.65 )
Ranked among companies with meaningful P/E(ttm) only.
VASC' s P/E(ttm) Range Over the Past 10 Years
Min: 5.09  Med: 25.87 Max: 447.5
Current: 79.65
5.09
447.5
Forward P/E 38.02
VASC's Forward P/E is ranked lower than
81% of the 54 Companies
in the Global Medical Devices industry.

( Industry Median: 21.74 vs. VASC: 38.02 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 79.65
VASC's PE(NRI) is ranked lower than
85% of the 172 Companies
in the Global Medical Devices industry.

( Industry Median: 25.53 vs. VASC: 79.65 )
Ranked among companies with meaningful PE(NRI) only.
VASC' s PE(NRI) Range Over the Past 10 Years
Min: 5.09  Med: 25.87 Max: 447.5
Current: 79.65
5.09
447.5
P/B 6.86
VASC's P/B is ranked lower than
78% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 3.08 vs. VASC: 6.86 )
Ranked among companies with meaningful P/B only.
VASC' s P/B Range Over the Past 10 Years
Min: 2.37  Med: 4.17 Max: 17.29
Current: 6.86
2.37
17.29
P/S 6.13
VASC's P/S is ranked lower than
75% of the 294 Companies
in the Global Medical Devices industry.

( Industry Median: 3.02 vs. VASC: 6.13 )
Ranked among companies with meaningful P/S only.
VASC' s P/S Range Over the Past 10 Years
Min: 1.37  Med: 2.63 Max: 6.16
Current: 6.13
1.37
6.16
POCF 76.89
VASC's POCF is ranked lower than
95% of the 134 Companies
in the Global Medical Devices industry.

( Industry Median: 18.20 vs. VASC: 76.89 )
Ranked among companies with meaningful POCF only.
VASC' s POCF Range Over the Past 10 Years
Min: 9.09  Med: 16.43 Max: 83.57
Current: 76.89
9.09
83.57
EV-to-EBIT 70.38
VASC's EV-to-EBIT is ranked lower than
88% of the 169 Companies
in the Global Medical Devices industry.

( Industry Median: 21.46 vs. VASC: 70.38 )
Ranked among companies with meaningful EV-to-EBIT only.
VASC' s EV-to-EBIT Range Over the Past 10 Years
Min: -155.5  Med: 15.9 Max: 183.7
Current: 70.38
-155.5
183.7
EV-to-EBITDA 47.14
VASC's EV-to-EBITDA is ranked lower than
83% of the 182 Companies
in the Global Medical Devices industry.

( Industry Median: 16.23 vs. VASC: 47.14 )
Ranked among companies with meaningful EV-to-EBITDA only.
VASC' s EV-to-EBITDA Range Over the Past 10 Years
Min: -424.7  Med: 13.35 Max: 1250.8
Current: 47.14
-424.7
1250.8
PEG 16.67
VASC's PEG is ranked lower than
89% of the 74 Companies
in the Global Medical Devices industry.

( Industry Median: 2.33 vs. VASC: 16.67 )
Ranked among companies with meaningful PEG only.
VASC' s PEG Range Over the Past 10 Years
Min: 0.45  Med: 2.6 Max: 4000
Current: 16.67
0.45
4000
Shiller P/E 83.71
VASC's Shiller P/E is ranked lower than
78% of the 49 Companies
in the Global Medical Devices industry.

( Industry Median: 46.10 vs. VASC: 83.71 )
Ranked among companies with meaningful Shiller P/E only.
VASC' s Shiller P/E Range Over the Past 10 Years
Min: 41.86  Med: 58.98 Max: 572.5
Current: 83.71
41.86
572.5
Current Ratio 6.37
VASC's Current Ratio is ranked higher than
85% of the 327 Companies
in the Global Medical Devices industry.

( Industry Median: 2.43 vs. VASC: 6.37 )
Ranked among companies with meaningful Current Ratio only.
VASC' s Current Ratio Range Over the Past 10 Years
Min: 1.94  Med: 5.36 Max: 26.32
Current: 6.37
1.94
26.32
Quick Ratio 4.66
VASC's Quick Ratio is ranked higher than
80% of the 327 Companies
in the Global Medical Devices industry.

( Industry Median: 1.82 vs. VASC: 4.66 )
Ranked among companies with meaningful Quick Ratio only.
VASC' s Quick Ratio Range Over the Past 10 Years
Min: 1.36  Med: 3.91 Max: 25.52
Current: 4.66
1.36
25.52
Days Inventory 151.53
VASC's Days Inventory is ranked lower than
59% of the 290 Companies
in the Global Medical Devices industry.

( Industry Median: 134.83 vs. VASC: 151.53 )
Ranked among companies with meaningful Days Inventory only.
VASC' s Days Inventory Range Over the Past 10 Years
Min: 130.39  Med: 149.76 Max: 182.03
Current: 151.53
130.39
182.03
Days Sales Outstanding 52.24
VASC's Days Sales Outstanding is ranked higher than
71% of the 277 Companies
in the Global Medical Devices industry.

( Industry Median: 66.89 vs. VASC: 52.24 )
Ranked among companies with meaningful Days Sales Outstanding only.
VASC' s Days Sales Outstanding Range Over the Past 10 Years
Min: 47.41  Med: 50.18 Max: 54.98
Current: 52.24
47.41
54.98
Days Payable 27.06
VASC's Days Payable is ranked lower than
81% of the 258 Companies
in the Global Medical Devices industry.

( Industry Median: 57.49 vs. VASC: 27.06 )
Ranked among companies with meaningful Days Payable only.
VASC' s Days Payable Range Over the Past 10 Years
Min: 21.44  Med: 37.58 Max: 43.39
Current: 27.06
21.44
43.39

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -2.00
VASC's 3-Year Average Share Buyback Ratio is ranked higher than
59% of the 209 Companies
in the Global Medical Devices industry.

( Industry Median: -3.90 vs. VASC: -2.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
VASC' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -53.7  Med: -2.7 Max: 0.4
Current: -2
-53.7
0.4

Valuation & Return

vs
industry
vs
history
Price/Net Cash 39.26
VASC's Price/Net Cash is ranked lower than
76% of the 98 Companies
in the Global Medical Devices industry.

( Industry Median: 16.84 vs. VASC: 39.26 )
Ranked among companies with meaningful Price/Net Cash only.
VASC' s Price/Net Cash Range Over the Past 10 Years
Min: 0.56  Med: 24.36 Max: 539.5
Current: 39.26
0.56
539.5
Price/Net Current Asset Value 12.91
VASC's Price/Net Current Asset Value is ranked lower than
74% of the 196 Companies
in the Global Medical Devices industry.

( Industry Median: 6.51 vs. VASC: 12.91 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
VASC' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 0.48  Med: 6.9 Max: 28.94
Current: 12.91
0.48
28.94
Price/Tangible Book 7.84
VASC's Price/Tangible Book is ranked lower than
74% of the 266 Companies
in the Global Medical Devices industry.

( Industry Median: 4.06 vs. VASC: 7.84 )
Ranked among companies with meaningful Price/Tangible Book only.
VASC' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.46  Med: 5.03 Max: 16.59
Current: 7.84
0.46
16.59
Price/Projected FCF 4.85
VASC's Price/Projected FCF is ranked lower than
77% of the 124 Companies
in the Global Medical Devices industry.

( Industry Median: 1.97 vs. VASC: 4.85 )
Ranked among companies with meaningful Price/Projected FCF only.
VASC' s Price/Projected FCF Range Over the Past 10 Years
Min: 1.39  Med: 2.3 Max: 130.33
Current: 4.85
1.39
130.33
Price/Median PS Value 2.33
VASC's Price/Median PS Value is ranked lower than
90% of the 231 Companies
in the Global Medical Devices industry.

( Industry Median: 1.02 vs. VASC: 2.33 )
Ranked among companies with meaningful Price/Median PS Value only.
VASC' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.31  Med: 1.15 Max: 12.76
Current: 2.33
0.31
12.76
Price/Graham Number 5.27
VASC's Price/Graham Number is ranked lower than
80% of the 134 Companies
in the Global Medical Devices industry.

( Industry Median: 2.31 vs. VASC: 5.27 )
Ranked among companies with meaningful Price/Graham Number only.
VASC' s Price/Graham Number Range Over the Past 10 Years
Min: 0.88  Med: 2.34 Max: 10.48
Current: 5.27
0.88
10.48
Earnings Yield (Greenblatt) (%) 1.40
VASC's Earnings Yield (Greenblatt) (%) is ranked higher than
53% of the 315 Companies
in the Global Medical Devices industry.

( Industry Median: 0.90 vs. VASC: 1.40 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
VASC' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.5  Med: 5.4 Max: 10.3
Current: 1.4
0.5
10.3
Forward Rate of Return (Yacktman) (%) 0.77
VASC's Forward Rate of Return (Yacktman) (%) is ranked lower than
72% of the 121 Companies
in the Global Medical Devices industry.

( Industry Median: 9.23 vs. VASC: 0.77 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
VASC' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -10.9  Med: 2.6 Max: 54.1
Current: 0.77
-10.9
54.1

More Statistics

Revenue (TTM) (Mil) $160.4
EPS (TTM) $ 0.70
Beta0.94
Short Percentage of Float5.89%
52-Week Range $24.34 - 57.15
Shares Outstanding (Mil)17.57

Analyst Estimate

Dec16 Dec17
Revenue (Mil $) 166 187
EPS ($) 1.23 1.47
EPS w/o NRI ($) 1.23 1.47
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for NAS:VASC

Headlines

Articles On GuruFocus.com
Mairs & Power Comments on Vascular Solutions Dec 01 2015 
Vascular Solutions Inc. Reports Operating Results (10-K) Feb 01 2011 
Vascular Solutions Inc. (VASC) CEO Howard Root sells 25,000 Shares Nov 04 2010 
Vascular Solutions Inc. Reports Operating Results (10-K) Feb 02 2010 
Vascular Solutions Inc. Reports Operating Results (10-Q) Apr 17 2009 

More From Other Websites
VASCULAR SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces the Investigation of Vascular Solutions,... Dec 09 2016
INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Whether the Sale of... Dec 07 2016
Hedge Funds Continue to Hold On To Quality Systems, Inc. (QSII) Dec 05 2016
VASCULAR SOLUTIONS, INC. SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe and Powers Taylor LLP... Dec 05 2016
Ryan & Maniskas, LLP Announces Investigation of Vascular Solutions, Inc. Dec 05 2016
Company News for December 05, 2016 Dec 05 2016
Blog Coverage Teleflex Set to Acquire Vascular Solutions Dec 05 2016
Vascular Solutions downgraded by Piper Jaffray Dec 05 2016
VASCULAR SOLUTIONS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti,... Dec 03 2016
VASCULAR SOLUTIONS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in... Dec 02 2016
Harwood Feffer LLP Announces Investigation of Vascular Solutions, Inc. Dec 02 2016
Teleflex To Acquire Vascular Solutions for $1B (TFX) Dec 02 2016
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Whether the Sale of... Dec 02 2016
VASCULAR SOLUTIONS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout Dec 02 2016
Medical Device Companies Vascular Solutions, Teleflex Agree to $1 Billion Merger Dec 02 2016
VASCULAR (VASC) ALERT: Johnson & Weaver, LLP Launches an Investigation into the Fairness of Price... Dec 02 2016
Vascular to be bought by Teleflex in a $1 billion deal Dec 02 2016
Vascular Solutions to be Acquired by Teleflex Incorporated Dec 02 2016
3 Hot Healthcare Stocks with Great Momentum Nov 24 2016
ETF’s with exposure to Vascular Solutions, Inc. : November 7, 2016 Nov 07 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)